A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Chronic Kidney Disease
- Sponsor
- Lawson Health Research Institute
- Enrollment
- 822
- Locations
- 1
- Primary Endpoint
- Renal decline
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The investigators have designed a randomized controlled trial to test whether increased water intake slows renal decline in patients with Stage-III Chronic Kidney Disease. Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual fluid intake, for one year. The investigators will calculate the change in kidney function (estimated glomerular filtration rate, measured every three months for 12 months), and compare renal decline between the intervention and control groups. The investigators hypothesize that increased water intake will slow renal decline.
Investigators
William Clark
Principle Investigator
Lawson Health Research Institute
Eligibility Criteria
Inclusion Criteria
- •Age 18-80 years
- •Able to provide informed consent and willing to complete follow-up visits.
- •Estimated glomerular filtration rate between 30 and 60 ml/min/1.73m2
- •Trace protein or greater (Albustix) or urine albumin/creatinine ratio \>2.8 mg/mmol (if female) or \>2.0 mg/mmol (if male) from a random spot urine sample
Exclusion Criteria
- •Self-reported fluid intake \>10 cups/day or 24-hr urine volume \>3L.
- •Enrolled in another trial that could influence the intervention, outcomes or data collection of this trial (or previously enrolled in this trial)
- •Received one or more dialysis treatments in the past month
- •Kidney transplant within past six months (or on waiting list)
- •Pregnant or breastfeeding
- •History of kidney stones in past 5 years
- •Less than two years life expectancy
- •Serum sodium \<130 mEq/L without suitable explanation
- •Serum calcium \>2.6 mmol/L without suitable explanation
- •Currently taking hydrochlorothiazide \>25 mg/d, indapamide \>1.25 mg/d, furosemide \>40 mg, or metolazone \>2.5 mg/d
Outcomes
Primary Outcomes
Renal decline
Time Frame: Baseline and 12 months
Change in estimated glomerular filtration rate between baseline and 12 months
Secondary Outcomes
- Rapid renal decline(Baseline and 12 months)
- Copeptin(Baseline and 12 months)
- 24-hour urine albumin(Baseline and 12 months)
- Measured creatinine clearance(Baseline and 12 months)
- Health-related quality of life(Baseline and 12 months)